Observe Medical ASA (OSL:OBSRV) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:OBSRV Observe Medical ASA OSL:OBSRV
29 GF Score
Price kr0.94
GF Value kr0.21
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Observe Medical ASA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Observe Medical ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr22.58 Mil. Observe Medical ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was kr19.74 Mil. Observe Medical ASA's annualized EBITDA for the quarter that ended in Jun. 2026 was kr20.39 Mil. Observe Medical ASA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 2.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Observe Medical ASA's Debt-to-EBITDA or its related term are showing as below:

OSL:OBSRV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.64   Med: -1.24   Max: 3.8
Current: -3.57

During the past 8 years, the highest Debt-to-EBITDA Ratio of Observe Medical ASA was 3.80. The lowest was -4.64. And the median was -1.24.

OSL:OBSRV's Debt-to-EBITDA is ranked worse than
100% of 471 companies
in the Medical Devices & Instruments industry
Industry Median: 1.64 vs OSL:OBSRV: -3.57

Observe Medical ASA  (OSL:OBSRV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Observe Medical ASA Debt-to-EBITDA Related Terms


Observe Medical ASA Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Observe Medical ASA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Observe Medical ASA Debt-to-EBITDA Chart

Observe Medical ASA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial - - - - -

Observe Medical ASA Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OSL:OBSRV vs ABT, SYK, MDT: Debt-to-EBITDA Comparison

For the Medical Devices subindustry, Observe Medical ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Observe Medical ASA Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Observe Medical ASA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Observe Medical ASA's Debt-to-EBITDA falls into.


OSL:OBSRV
29GF Score
Observe Medical ASA OSL:OBSRV
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Observe Medical ASA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Observe Medical ASA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.822 + 19.919) / -30.15
=-1.02

Observe Medical ASA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(22.577 + 19.737) / 20.392
=2.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.

Is Observe Medical ASA (OSL:OBSRV) Overvalued in 2026?

Based on GuruFocus' analysis, Observe Medical ASA stock appears to be overvalued. The current stock price of kr0.94 is trading 349.5% above its estimated GF Value™ of kr0.21. GuruFocus considers Observe Medical ASA to be Significantly Overvalued.

Key valuation signals for OSL:OBSRV:

  • Debt-to-EBITDA:
  • GF Value™: kr0.21 vs. price of kr0.94 (349.5% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the OSL:OBSRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Observe Medical ASA Business Description

Other Exchanges OM50:Germany
Address Dronning Eufemias gate 16, Oslo, NOR, 0191
Observe Medical ASA is a Nordic medtech company focused on the development, commercialization, and scaling of medical technologies for the healthcare markets. The company's portfolio of proprietary products consists of: Sippi, a CE marked digitalized system for urine output measurement, the UnoMeter portfolio consisting of manual urine output measurement products and solutions for measuring intra-abdominal pressure. The company operates internationally through subsidiaries in Norway, Sweden and Denmark.
29GF Score

Get the complete analysis for OSL:OBSRV

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.94
Price
kr0.21
GF Value